Cardiac electrical instability in Erdheim-Chester disease: a case report
Authors:
- Andrea UrbaniAUAndrea Urbani
- Filippo PensottiFPFilippo Pensotti
- Diego CastiniDCDiego Castini
- Silvia MagnaniSMSilvia Magnani
- Pasquale Simone SimeoliPSPasquale Simone Simeoli
- Corrado CampochiaroCorrado Campochiaro
- Lorenzo DagnaLDLorenzo Dagna
- Alberto M CappellettiACAlberto M Cappelletti
- Carlo SponzilliCSCarlo Sponzilli
- Marco GuazziMGMarco Guazzi
Open Access
- 26 July 2022
- journal article
- research article
- Published by Oxford University Press (OUP) in Oxford Medical Case Reports
- Vol. 2022 (7) , omac071
Abstract
Erdheim-Chester disease (ECD) is a rare multisystemic disorder of non-Langerhans histiocytic cells with a pleomorphic clinical presentation. It affects bones, skin, central nervous system, pituitary gland, ocular tissue, kidneys and perirenal tissue and lungs. Cardiac involvement presents usually with pericardial effusion and right atrial masses, but rarely with conduction system infiltration and subsequent arrhythmic events. Following the discovery of mutations of activating signaling kinase proteins (BRAF, MEK, ALK), the therapeutic landscape has changed to a more precise targeted treatment. Currently vemurafenib is approved for patient with end-organ dysfunction and BRAF-V600E mutation and the prognosis has dramatically improved. Here we present a case of ECD with electrical instability as main clinically relevant manifestation of cardiac involvement.Keywords
This publication has 9 references indexed in Scilit:
- Efficacy and improved tolerability of combination therapy with interleukin-1 blockade and MAPK pathway inhibitors for the treatment of Erdheim-Chester diseaseAnnals of the Rheumatic Diseases, 2022
- Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular eraBlood, 2020
- Cardiothoracic manifestations of Erdheim-Chester diseaseBritish Journal of Radiology, 2019
- Cardiovascular manifestations of Erdheim–Chester diseaseEchocardiography, 2018
- Treating Heart Inflammation With Interleukin-1 Blockade in a Case of Erdheim–Chester DiseaseFrontiers in Immunology, 2018
- Vemurafenib for BRAF V600–Mutant Erdheim-Chester Disease and Langerhans Cell HistiocytosisJAMA Oncology, 2018
- Phenotypes and survival in Erdheim‐Chester disease: Results from a 165‐patient cohortAmerican Journal of Hematology, 2018
- Diverse and Targetable Kinase Alterations Drive Histiocytic NeoplasmsCancer Discovery, 2016
- Erdheim-Chester diseaseEuropean Journal of Internal Medicine, 2015